Tags: oncology, lung cancer, ADC, phase 3, Seagen

Pfizer's Seagen-derived lung cancer ADC misses the main phase 3 survival bar

By FieldPulse Editorial · June 22, 2026

Pfizer said sigvotatug vedotin missed the primary overall-survival endpoint against docetaxel in phase 3 NSCLC, though the company continues to push the program forward.

Pfizer reported a meaningful setback for one of the more closely watched assets it picked up through Seagen.

In a company press release, Pfizer said sigvotatug vedotin did not show a statistically significant improvement in overall survival versus docetaxel in the phase 3 SigVie-002 study of previously treated metastatic non-squamous non-small cell lung cancer.

That is the headline field teams need to keep exact.

The study missed its primary endpoint in the overall population.

Pfizer also said the drug's safety profile was manageable and consistent with prior studies, and it pointed to a stronger trend for overall survival and progression-free survival in patients treated in the second-line setting.

For Pfizer oncology teams, this is the kind of readout that can trigger fast questions from data-focused customers, especially because the program had been seen as an important part of the company's post-Seagen ADC strategy.

The message should stay narrow: the main phase 3 survival bar was not met, but Pfizer is continuing development and still has an ongoing first-line phase 3 study, SigVie-003, combining sigvotatug vedotin with pembrolizumab in PD-L1-positive NSCLC.

For competitors, this is useful intelligence, but not a reason to overstate failure.

The commercial pressure from this asset looks lower in the near term after the overall miss, yet Pfizer is still signaling continued commitment to the program in earlier-line disease.